Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

BG-89894

Small molecule · Inhibitor of methionine adenosyltransferase II alpha (MAT2A) · developed by BeOne Medicines

Phase 1 Most advanced trial
ONC Developer
1 Registered trials

What is BG-89894?

BG-89894 is an orally bioavailable inhibitor of MAT2A, the metabolic enzyme that produces S-adenosyl-L-methionine, the main methyl donor for cellular transmethylation. It is being studied in advanced solid tumors, including MTAP-deleted cancers that depend heavily on SAM synthesis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Targets
methionine adenosyltransferase II alpha (MAT2A)
Mechanism
Inhibitor of methionine adenosyltransferase II alpha (MAT2A)
Pathways
S-adenosyl-L-methionine synthesis, transmethylation reactions, methionine salvage pathway
Therapy area
Oncology
Developer
BeOne Medicines (ONC)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06589596 Phase 1 Advanced Solid Tumor Recruiting ONC

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Solid Tumor

Other drugs acting on MAT2A

More from BeOne Medicines

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the ONC page.

Follow ONC, the company behind BG-89894

See ONC's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ONC catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.